What Leuprolide is
Leuprolide is a GnRH analog that alters pituitary-gonadal signaling in approved clinical contexts.
Leuprolide is grouped under Approved / Clinical on PeptideFactCheck because it shows peptide analog engineering at the serious end of clinical pharmacology.
The useful starting point is to separate the molecule itself from the internet story around it. It is a strong example of peptide analogs affecting major endocrine systems.
Why people keep looking it up
People associate leuprolide with hormone suppression.
Leuprolide changes pituitary-gonadal signaling through GnRH receptor biology.
Leuprolide tends to stay in the conversation because it touches a familiar public theme: gnrh analog, pituitary signaling, and hormonal suppression. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
It is an approved clinical drug, not a performance peptide.
Human clinical evidence and official labels support specific uses.
Mechanism follows GnRH receptor biology and endocrine feedback.
Why this page carries the current tier: Approved peptide analog with extensive clinical use.
The current seed trail for Leuprolide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Hormonal suppression is not an optimization claim and requires medical context.
FDA-approved leuprolide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Leuprolide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Leuprolide is CID 657181. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 657181
- Formula
- C59H84N16O12
- Molecular weight
- 1209.4
- InChIKey
- GFIJNRVAKGFPGQ-LIJARHBVSA-N
Matched synonyms include Leuprorelin, leuprolide, 53714-56-0, Leuproreline, Leuprorelinum, Leuporelin, Leuprorelina, (-)-leuprolide.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Leuprolide returns 505 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Leuprolide returns 4210 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Vabrinty
- Generic names
- LEUPROLIDE ACETATE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA021379, NDA021488, NDA021731, NDA021343
Indications and usage. 1 INDICATIONS AND USAGE VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Tumor Flare: Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate. ( 5.1 , 5.7 ) Hyp...
Contraindications. 4 CONTRAINDICATIONS Hypersensitivity VABRINTY is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs or any of the components of VABRINTY. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Known hypersensitivity to GnRH, GnRH agonist analogs or any of the components of VABRINTY ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.